@article{9bb78ab0924f46c28ea27c903e7f712e,
title = "Network meta-analyses should be the highest level of evidence in treatment guidelines",
author = "Stefan Leucht and Anna Chaimani and Cipriani, \{Andrea S.\} and Davis, \{John M.\} and Furukawa, \{Toshi A.\} and Georgia Salanti",
note = "Funding Information: In the last three years, Stefan Leucht has received honoraria for lectures from EliLilly, Lundbeck (Institute), Pfizer, Janssen, BMS, Johnson and Johnson, Otsuka, Roche, SanofiAventis, ICON, Abbvie, AOP Orphan, Servier; for consulting/advisory boards from Roche, Janssen, Lundbeck, EliLilly, Otsuka, TEVA; for the preparation of educational material and publications from Lundbeck Institute and Roche. EliLilly has provided medication for a clinical trial led by SL as principal investigator. Andrea Cipriani was expert witness for Accord Healthcare for a patent issue about quetiapine extended release. Toshi A Furukawa has received lecture fees from Eli Lilly, Janssen, Meiji, MSD, Otsuka, Pfizer and Tanabe-Mitsubishi, and consultancy fees from Sekisui Chemicals and Takeda Science Foundation. He has received royalties from Igaku-Shoin and Nihon Bunka Kagaku-sha publishers. He has received grant or research support from the Japanese Ministry of Education, Science, and Technology, the Japanese Ministry of Health, Labour and Welfare, the Japan Society for the Promotion of Science, the Japan Foundation for Neuroscience and Mental Health, Mochida and Tanabe-Mitsubishi.",
year = "2016",
month = sep,
day = "1",
doi = "10.1007/s00406-016-0715-4",
language = "English",
volume = "266",
pages = "477--480",
journal = "European Archives of Psychiatry and Clinical Neuroscience",
issn = "0940-1334",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "6",
}